The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the market in the coming years.

Epigenetics Market Dynamics: Impact Analysis

1. Global Market for Epigenetics: Developed vs Developing Countries
2. Rising Cancer Prevalence
3. Increasing Research Activities
4. Declining Sequencing Costs and Time
5. High Growth Potential in Emerging Markets
6. Growing Applications of Epigenetics in Personalized Medicine
7. Use of Epigenetics in Non-Oncology Applications

The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%.

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global Epigenetics market?
2. What are the drivers, restraints, opportunities, and challenges in the Epigenetics Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of Epigenetics in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896

Epigenetics refers to the covalent modification of DNA, RNA, or protein that results in changes to the function and/or regulation of these molecules, without altering their primary sequences. These modifications can occur naturally, or can be influenced, by several factors including age, environment, disease state, and changes in lifestyle.

Epigenetics Products:

Based on product, the global epigenetics market is segmented into enzymes, instruments and consumables, kits, reagents and bioinformatics tools. The kits segment is expected to grow at the highest CAGR of 16.2% from 2017-2022 due to the fact that a large number of kits are used in various epigenetics techniques. The rising prevalence of a number of diseases, increasing R&D spending, and growing government funding for life science research are further contributing to market growth in this segment.

Applications of Epigenetics:

Oncology is one of those applications where epigenetics technology is extensively used for deriving therapeutic strategies designed to reverse transcriptional abnormalities inherent to the cancer epigenome. The disruption of epigenetic modifications, such as DNA methylation and histone modification, results in altered gene function or expression and cellular transformation leading cancer. Epigenetics assists in the development of inhibitors of DNA methyltransferases and histone deacetylases (HDACs), which have been found to be clinically effective in cancer treatment, attesting to the value of epigenetic therapies in oncology.

Regional Growth Analysis:

The epigenetics market in Asia-Pacific region is expected to witness the highest CAGR during the forecast period of 2017 to 2022. The growth of this segment can be attributed to the increasing R&D spending, increasing government initiatives, and rising focus on key market players in the region. Emerging markets such as Brazil, China, and India offer significant growth potential to market players.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=896

Key Players:

The global epigenetics market is characterized by a large number of players. The prominent players of this market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), Bio-Rad (US). These companies are pursuing several organic and inorganic growth strategies such as acquisitions, collaboration, partnerships, agreements, expansions, and product launches.